Cinar Celal, Elek Alperen, Kusbeci Mahmut, Ozturk Egemen, Utli Cemre Yanbol, Oran Ismail
Department of Interventional Radiology, Faculty of Medicine, Ege University, Izmir, Turkey.
Neuroradiology. 2025 May 22. doi: 10.1007/s00234-025-03653-7.
We aim to retrospectively evaluate patients treated with SVB at our single center, assessing its efficacy, radiologic and clinical outcomes, and complication profile.
This retrospective, single-center study included patients with small parent artery aneurysms treated with SVB. Patients were monitored for procedural success, aneurysm occlusion, and complications, with radiologic and clinical follow-up conducted.
The study included 64 patients with 66 small parent artery aneurysms treated using SVB FDs. Among these patients, 26 (40.6%) presented with subarachnoid hemorrhage (SAH). The mean index aneurysm size was 5.7 ± 5.25 mm. The cohort consisted of 15 males (23.4%) and 49 females (76.6%), with a mean age of 54.23 ± 14.95 years (range: 5-80 years). SVB was used as a standalone treatment in 42 patients (65.6%), while adjunctive materials were applied in 22 cases (34.4%)-coils in 16 (24.2%) and a regular stent in 6 (9.1%). A total of 71 SVB stents were deployed for 66 aneurysms, achieving a 100% technical success rate. In 30 patients with multiple aneurysms, additional aneurysms were addressed during the same session along with the index aneurysm. The mean duration of clinical and radiological follow-up was 10.5 ± 7.94 months. Among a total of 7 patients (10.9%) with ischemic complications, 3 (4.7%) were related to SVB implantation. Index aneurysm occlusion was accomplished in 93.3% of cases at the last follow-up. Favorable neurological outcomes (mRS 0-2) were recorded in 53 patients (82.8%). Subgroup analysis showed that 6 out of 7 total complications (85.7%) occurred in patients with multiple aneurysms.
The SVB FDs are a highly effective and safe treatment option for distal intracranial aneurysms, achieving high occlusion rates with a favorable safety profile.
我们旨在回顾性评估在我们单中心接受分流血管桥接（SVB）治疗的患者，评估其疗效、影像学和临床结果以及并发症情况。
这项回顾性单中心研究纳入了接受SVB治疗的小载瘤动脉动脉瘤患者。对患者进行手术成功率、动脉瘤闭塞情况及并发症监测，并进行影像学和临床随访。
该研究纳入了64例使用SVB分流装置（FDs）治疗66个小载瘤动脉动脉瘤的患者。其中，26例（40.6%）出现蛛网膜下腔出血（SAH）。索引动脉瘤的平均大小为5.7±5.25毫米。该队列包括15名男性（23.4%）和49名女性（76.6%），平均年龄为54.23±14.95岁（范围：5 - 80岁）。42例患者（65.6%）将SVB作为独立治疗方法，22例（34.4%）应用了辅助材料——16例（24.2%）使用了弹簧圈，6例（9.1%）使用了普通支架。共为66个动脉瘤植入了71个SVB支架，技术成功率达到100%。在30例患有多个动脉瘤的患者中，在同一手术过程中对索引动脉瘤及其他动脉瘤进行了治疗。临床和影像学随访的平均时长为10.5±7.94个月。在总共7例（10.9%）出现缺血性并发症的患者中，3例（4.7%）与SVB植入有关。在最后一次随访时，93.3%的病例实现了索引动脉瘤闭塞。53例患者（82.8%）获得了良好的神经功能预后（改良Rankin量表评分0 - 2分）。亚组分析显示，7例总并发症中的6例（85.7%）发生在患有多个动脉瘤的患者中。
SVB分流装置是治疗颅内远端动脉瘤的一种高效且安全的治疗选择，闭塞率高且安全性良好。
